Undisclosed RNA interference therapeutic / City Therapeutics, Bausch Health - LARVOL DELTA

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy (Businesswire) - "City Therapeutics, Inc...today announced that it has entered into a strategic collaboration with global eye health leader Bausch + Lomb focused on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) that causes irreversible vision loss...Under terms of the collaboration, City Therapeutics has received an upfront cash payment and, if Bausch + Lomb elects to pursue a candidate for further development, City Therapeutics is also eligible to receive contingent payments tied to development, regulatory, commercial and sales milestones of up to $485 million, as well as tiered royalty payments on net product sales."

Commercial • Age-related Macular Degeneration